THERAPY DOSSIER · th-69876ae11099

Electrospun chitosan/polyvinyl alcohol nanofibre mats, prepared with chitosan aqueous salts formed using hydroxybenzotriazole, thiamine pyrophosphate or EDTA

Device · Device (electrospun chitosan/PVA nanofibre mats); not a ChEMBL entity

Evidence & regulatory context

Mechanism: Device (electrospun chitosan/PVA nanofibre mats); not a ChEMBL entity
Target: Not recorded
Injury models: Wound
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 22925275 ↗2012Reported benefit

Electrospun chitosan/polyvinyl alcohol nanofibre mats for wound healing.

RatWoundWistarMaleTopical application as a wound dressing

Model: Acute excisional skin wound used for in vivo wound healing testing of dressings

Chitosan-EDTA/polyvinyl alcohol nanofibre mats decreased acute wound size more than gauze during the first week after wounding. The mats were non-toxic to normal human fibroblasts and the chitosan-hydroxybenzotriazole and chitosan-EDTA formulations showed antibacterial activity.

Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…